Please login to the form below
OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy
Written by Gavin Jones, OPEN Health
The FDA has published their industry guidance on the topic of long term follow up (LTFU) post gene therapy. Please see a link to the full guidance below. In summary, they are stipulating that a good proportion of these therapies will require LTFU of up to fifteen years.
This presents significant challenge to manufacturers given that patients will, in that stretch of time, have multiple changes to their care settings and life circumstances. In addition to this, and if these therapies live up to their promise, treated ‘patients’ will potentially become chronically well and keen to disengage from their previous disease state and their healthcare professionals.
This is a significant challenge but achievable! We have already shared our experienced thinking on this topic and a link to our article is provided below. Our recommendations focus on putting the patient at the centre of a solution and wrapping a, digitally enabled, registry solution around thoughtful patient and healthcare professional engagement.
Please read our full thinking below:
Get in touch
If you would like to discuss further please contact our director of rare disease: gavinjones@openhealthgroup.com
Company Details
OPEN Health
Address:
The Weighbridge
Brewery Courtyard
High Street
Marlow
Buckinghamshire
SL7 2FF
United Kingdom
Latest content on this profile
- OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health
- OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health
OPEN Health
- OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member
- OPEN Health has announced additions to its board of directors, appointing David P. King as non-executive Chairman and Paul Carter as an independent board member.
OPEN Health
- Steve Chick joins OPEN Health as Chief Growth Officer for Evidence & Access
- OPEN Health is pleased to announce the appointment of Stephen J. Chick as Chief Growth Officer for OPEN Health Evidence & Access.
OPEN Health
- OPEN Health to acquire leading US medical communications platform The CM Group from NaviMed Capital
- OPEN Health, a pre-eminent global provider of scientific communications and market access services, announced that it signed a binding agreement to acquire The CM Group, a leading US domestic medical communications platform from NaviMed Capital (“NaviMed”).
OPEN Health
- How digital health is changing the relationship between patients and health providers | OPEN Health
- The pandemic has forced pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes
OPEN Health
- David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access
- David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access
OPEN Health
